Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlodipine, Losartan, and Atenolol for Microvascular Function in SVD
NCT03082014Phase 3Terminated
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Feb 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of amlodipine, losartan, atenolol in Cerebral Small Vessel Disease (CSVD), cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), sponsored by Ludwig Maximilian University of Munich. Started Feb 2018; status: terminated.
02
Drugs
amlodipinelosartanatenolol
03
Conditions
Cerebral Small Vessel Disease (CSVD)cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
Beyond the preview
Go deeper on NCT03082014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082014.